Research
Hormonal
GLP-1 release is significantly blunted or absent in morbidly obese individuals and those with type 2 diabetes, contributing to dysregulated nutrient sensing and appetite control.
In obesity and type 2 diabetes, the body's natural production of GLP-1, a hormone that helps you feel full, is often blunted. This makes it physiologically harder to regulate food intake. Treatments that mimic GLP-1 (like GLP-1 agonists) work by restoring this signal, highlighting the importance of this pathway in weight management.
GoodSupportsHIGH confidence
GLP- 1 release was shown to be dramatically decreased during morbid obesity [44, 45]. The postprandial surge in GLP- 1 release was found to be virtually absent in morbidly obese subjects [46] and subjects with type 1 (T1D) and T2D [47].
Why this rating
Based on multiple cited studies showing blunted release.
Source
The Enteric Neuronal Circuitry: A Key Ignored Player in Nutrient Sensing Along the Gut–Brain Axis
Ester Nikolla et al. · The FASEB Journal · 2025
DOI 10.1096/fj.202500220rr
narrative_reviewCited 3×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- The enteric nervous system (ENS) directly senses luminal nutrients (glucose, fatty acids, amino acids) via specific receptors and ion channels on enteric neurons, independent of enteroendocrine cell intermediaries.Good
- Bariatric surgery, particularly Roux-en-Y gastric bypass (RYGB), restores GLP-1 secretion by rapidly delivering nutrients to the distal gut where L-cells are concentrated, leading to increased satiety and weight loss.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →